First prospective clinical evaluation of feasibility and patient acceptance of magnetic resonance-guided radiotherapy in Germany.


Journal

Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
ISSN: 1439-099X
Titre abrégé: Strahlenther Onkol
Pays: Germany
ID NLM: 8603469

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 23 10 2019
accepted: 07 01 2020
pubmed: 1 2 2020
medline: 15 12 2020
entrez: 1 2 2020
Statut: ppublish

Résumé

Magnetic resonance-guided radiotherapy (MRgRT) has recently been introduced in our institution. As MRgRT requires high patient compliance compared to conventional techniques and can be associated with prolonged treatment times, feasibility and patient tolerance were prospectively assessed using patient-reported outcome questionnaires (PRO-Q). Forty-three patients were enrolled in a prospective observational study and treated with MRgRT on a low-field hybrid Magnetic Resonance Linear Accelerator system (MR-Linac) between April 2018 and April 2019. For assistance in gated breath-hold delivery using cine-MRI, a video feedback system was installed. PRO-Qs consisted of questions on MR-related complaints and also assessed aspects of active patient participation. The most commonly treated anatomic sites were nodal metastases and liver lesions. The mean treatment time was 34 min with a mean beam-on time of 2:17 min. Gated stereotactic body radiotherapy (SBRT) was applied in 47% of all patients. Overall, patients scored MRgRT as positive or at least tolerable in the PRO‑Q. Almost two thirds of patients (65%) complained about at least one item of the PRO‑Q (score ≥4), mainly concerning coldness, paresthesia, and uncomfortable positioning. All patients reported high levels of satisfaction with their active role using the video feedback system in breath-hold delivery. MRgRT was successfully implemented in our clinic and well tolerated by all patients, despite MR-related complaints and complaints about uncomfortable immobilization. Prospective clinical studies are in development for further evaluation of MRgRT and for quantification of the benefit of MR-guided on-table adaptive radiotherapy.

Identifiants

pubmed: 32002567
doi: 10.1007/s00066-020-01578-z
pii: 10.1007/s00066-020-01578-z
pmc: PMC7385000
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

691-698

Références

Acta Oncol. 2015;54(9):1474-82
pubmed: 26206517
Cureus. 2018 Feb 27;10(2):e2236
pubmed: 29719739
Int J Radiat Oncol Biol Phys. 2018 Aug 1;101(5):1046-1056
pubmed: 30012524
Semin Radiat Oncol. 2014 Jul;24(3):196-9
pubmed: 24931092
Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):1086-1094
pubmed: 31419510
Semin Radiat Oncol. 2018 Jun;28(3):178-184
pubmed: 29933877
Lancet Oncol. 2006 Oct;7(10):848-58
pubmed: 17012047
Phys Med Biol. 2017 Nov 14;62(23):L41-L50
pubmed: 29135471
Radiat Oncol. 2019 Jun 3;14(1):92
pubmed: 31167658
J Magn Reson Imaging. 2007 Nov;26(5):1322-7
pubmed: 17969166
Adv Radiat Oncol. 2018 Oct 18;4(1):201-209
pubmed: 30706029
Radiother Oncol. 2019 Mar;132:16-22
pubmed: 30825964
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):858-866
pubmed: 30061007
Support Care Cancer. 2018 Jan;26(1):41-60
pubmed: 28849277
Adv Radiat Oncol. 2017 Jun 01;2(3):485-493
pubmed: 29114617
Strahlenther Onkol. 2018 May;194(5):425-434
pubmed: 29349601
Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):644-51
pubmed: 19427564
J Appl Clin Med Phys. 2017 May;18(3):163-169
pubmed: 28436094
Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):236-46
pubmed: 18722274
Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1078-1086
pubmed: 27742541
Radiat Oncol. 2014 Jan 09;9:12
pubmed: 24401489
Semin Radiat Oncol. 2014 Jul;24(3):193-5
pubmed: 24931091
Int J Radiat Oncol Biol Phys. 2018 Oct 1;102(2):426-433
pubmed: 29902559
Clin Transl Radiat Oncol. 2019 Apr 26;18:140-145
pubmed: 31341990
Dtsch Arztebl Int. 2011 Apr;108(16):274-80
pubmed: 21603562
Radiat Oncol. 2019 Apr 29;14(1):71
pubmed: 31036034
Cureus. 2017 Aug 27;9(8):e1618
pubmed: 29104835
Radiother Oncol. 2019 May;134:50-54
pubmed: 31005224
Clin Transl Radiat Oncol. 2019 Apr 08;18:98-101
pubmed: 31341983
Phys Med Biol. 2019 Aug 07;64(15):15TR01
pubmed: 31226704
JBI Libr Syst Rev. 2011;9(19):631-678
pubmed: 27820215
Adv Radiat Oncol. 2018 Aug 23;4(1):142-149
pubmed: 30706022
Radiother Oncol. 2019 Mar;132:114-120
pubmed: 30825959
Lancet. 1991 Sep 21;338(8769):761-2
pubmed: 1679897
Nat Rev Clin Oncol. 2012 Dec;9(12):688-99
pubmed: 23165124
Int J Radiat Oncol Biol Phys. 2018 Nov 15;102(4):987-995
pubmed: 29953910
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):686-691
pubmed: 30195605
Med Phys. 2017 Sep;44(9):4838-4846
pubmed: 28675492
Radiother Oncol. 2017 Dec;125(3):439-444
pubmed: 28811038
Clin Transl Radiat Oncol. 2019 Apr 02;18:54-59
pubmed: 31341976
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):711-719
pubmed: 30201276
Med Phys. 2018 May 28;:
pubmed: 29807390
Clin Oncol (R Coll Radiol). 2018 Nov;30(11):720-727
pubmed: 30197095

Auteurs

Sebastian Klüter (S)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Sonja Katayama (S)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

C Katharina Spindeldreier (CK)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Stefan A Koerber (SA)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Gerald Major (G)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Markus Alber (M)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Sati Akbaba (S)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.

Jürgen Debus (J)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany.
National Center for Tumor diseases (NCT), Heidelberg, Germany.
Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg Ion-Beam Therapy Center (HIT), Heidelberg, Germany.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Juliane Hörner-Rieber (J)

Department of Radiation Oncology, Heidelberg University Hospital, Im Neuenheimer Feld 400, 69120, Heidelberg, Germany. juliane.hoerner-rieber@med.uni-heidelberg.de.
Heidelberg Institute of Radiation Oncology (HIRO), Heidelberg, Germany. juliane.hoerner-rieber@med.uni-heidelberg.de.
National Center for Tumor diseases (NCT), Heidelberg, Germany. juliane.hoerner-rieber@med.uni-heidelberg.de.
Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany. juliane.hoerner-rieber@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH